These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14968815)

  • 1. Preclinical studies and clinical trials for diabetes-second annual forum: identifying emerging therapies and improve trial efficiency.
    Parker J
    IDrugs; 2004 Jan; 7(1):37-9. PubMed ID: 14968815
    [No Abstract]   [Full Text] [Related]  

  • 2. American Diabetes Association--63rd Scientific Sessions. Preclinical data. 13-17 June 2003, New Orleans, LA, USA.
    Evans L
    IDrugs; 2003 Aug; 6(8):725-6. PubMed ID: 12971383
    [No Abstract]   [Full Text] [Related]  

  • 3. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies in diabetes mellitus.
    Bandyopadhyay P
    Drug News Perspect; 2006 Oct; 19(8):499-507. PubMed ID: 17160152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 based therapy for type 2 diabetes.
    Arulmozhi DK; Portha B
    Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
    Brigance RP; Meng W; Fura A; Harrity T; Wang A; Zahler R; Kirby MS; Hamann LG
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4395-8. PubMed ID: 20598534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Diabetes Association--64th Scientific Sessions. Insulin. 4-8 June 2004, Orlando, FL, USA.
    Mazucco RA
    IDrugs; 2004 Jul; 7(7):631-2. PubMed ID: 15243860
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intensive insulin therapy: results after ten years].
    Laube H
    Pharm Unserer Zeit; 2001 Jan; 30(1):40-5. PubMed ID: 11233182
    [No Abstract]   [Full Text] [Related]  

  • 9. Beyond insulin: what else might help?
    Scheiner G
    Diabetes Self Manag; 2014; 31(1):30, 32-4. PubMed ID: 24640060
    [No Abstract]   [Full Text] [Related]  

  • 10. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
    Chen P; Caldwell CG; Mathvink RJ; Leiting B; Marsilio F; Patel RA; Wu JK; He H; Lyons KA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5853-7. PubMed ID: 17869513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
    Herman GA; Stein PP; Thornberry NA; Wagner JA
    Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral therapy of diabetes mellitus by combination of hypoglycemic agents].
    Grujić M; Perinović M; Rizvanbegović B
    Med Arh; 1976; 30(3):167-71. PubMed ID: 979364
    [No Abstract]   [Full Text] [Related]  

  • 13. [Away with the needle. Noninvasive administration routes for insulin: improved quality of life for diabetics?].
    Simon M; Kissel T
    Pharm Unserer Zeit; 2001; 30(2):136-41. PubMed ID: 11279984
    [No Abstract]   [Full Text] [Related]  

  • 14. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
    Inzucchi SE; McGuire DK
    Circulation; 2008 Jan; 117(4):574-84. PubMed ID: 18227398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS; Madsbad S
    Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why most oral insulin formulations do not reach clinical trials.
    Lopes M; Simões S; Veiga F; Seiça R; Ribeiro A
    Ther Deliv; 2015; 6(8):973-87. PubMed ID: 26272222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of combined therapy by insulin and hypoglycemic drugs in diabetes].
    Daoud D; Karnieli E
    Harefuah; 1993 Mar; 124(5):281-5. PubMed ID: 8495920
    [No Abstract]   [Full Text] [Related]  

  • 18. Expanding treatment options for type 2 diabetes: the old and the new.
    Pratley RE
    Diabetes Educ; 2009; 35 Suppl 1():4S-11S. PubMed ID: 19218561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reevaluating goals of insulin therapy: perspectives from large clinical trials.
    Riddle MC; Yuen KC
    Endocrinol Metab Clin North Am; 2012 Mar; 41(1):41-56. PubMed ID: 22575406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.
    Ristic S; Bates PC
    Drugs Today (Barc); 2006 Aug; 42(8):519-31. PubMed ID: 16969429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.